Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78
Research Alert: Ew Reports Q1 Results, Posting Strong Operating Margins
Edwards Lifesciences Is Maintained at Neutral by Baird
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Resmed (RMD) and Thermo Fisher (TMO)
Edwards Lifesciences Analyst Ratings
Piper Sandler Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $80
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $75
Edwards Lifesciences: Hold Rating Amid Strong Q1 Results and Future Challenges
Stifel Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Edwards Lifesciences (EW) Gets a Buy From Stifel Nicolaus
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), UnitedHealth (UNH) and Edwards Lifesciences (EW)
Leerink Partners Maintains Edwards Lifesciences(EW.US) With Hold Rating, Announces Target Price $77
Leerink Partners Maintains Edwards Lifesciences(EW.US) With Hold Rating
Hold Rating Maintained for Edwards Lifesciences Amidst Positive Developments in Mitral Valve Approval and TAVR Challenges
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating
Edwards Lifesciences (EW) Gets a Buy From Citi
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $75
Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Announces Target Price $75
Edwards Lifesciences Price Target Cut to $75.00/Share From $78.00 by Truist Securities